BioSpace News Archive

The guide was developed by Ariadne Labs and The Conversation Project with generous support from the Cambia Health Foundation

Enzychem Lifesciences (KOSDAQ: 183490) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering treating COVID-19 infections and symptoms using EC-18, the Company’s lead compound.

Researchers and clinical experts at Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, are looking into the blood of COVID-19 survivors, as a potential treatment for current COVID-19 patients.

To investigate new experimental treatments to aid in the fight against COVID-19, The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today it has formally joined a national network formed by Mayo Clinic to collect convalescent plasma from patients previously identified with COVID-19, but no longer symptomatic.

Today, JobsOhio and Battelle announced a partnership to provide vital N95 respirator masks to health care professionals at Ohio hospitals, nursing homes and other medical facilities during the COVID-19 pandemic.

U.S. FDA Grants Emergency Use Authorization Solution Leverages Existing Equipment to Allow Hospitals to Decontaminate On-site

EOS imaging reschedules the publication of its results for the full year ended December 31, 2019. In the context of the COVID-19 health crisis, the Company has decided to postpone the date of publication of its annual result

The MEDICREA® Grouppublishes its 2019 IFRS annual results, as audited and approved by the Board of Directors on April 7, 2020, as well as its sales for the first quarter of 2020.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors has adopted a stockholder rights plan to replace BioSpecifics’ current rights plan, which has been terminated.

Otsuka America Pharmaceutical, Inc. announces today the extension of its patient support program to provide “no-cost” access to its branded portfolio of prescription medicines for patients in the U.S. who have lost a job or health insurance coverage due to the COVID-19 (coronavirus) pandemic.